Morten Mau‐Sørensen

Enhanced detection of circulating tumor DNA by fragment size analysis

Florent Moulière, Dineika Chandrananda, Anna Piskorz et al. · Science Translational Medicine · 2018 · 1.1K citations · Full text

Medicine, Molecular Biology, Oncology +13

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail et al. · Journal of Clinical Oncology · 2016 · 247 citations · Full text

Medicine, Oncology, Pharmacology +13

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

Benedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen et al. · Neuro-Oncology · 2010 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Christine Chen, David S. Siegel, Martin Gutierrez et al. · Blood · 2017 · 135 citations · Full text

Medicine, Hematology, Pharmacology +13

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Mark T. J. van Bussel, Ahmad Awada, Maja J.A. de Jonge et al. · British Journal of Cancer · 2020 · 127 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11